Closed Session Summary Posted After the Meeting
The following committee members were present at the closed sessions of the meeting:
Jonathan Samet (chair)
Scott Bartell
Lisa Bero
Ann Bostrom
Kay Dickersin
David Dorman
David Eaton
Joe Garcia
Miguel Hernán
James House (via teleconference)
Margaret MacDonell
Richard Scheines
Leonard Siegel
Robert Wallace
and Yiliang Zhu.
The following topics were discussed in the closed sessions:
1) Information presented in the open session and submitted to the committee.
2) Committee’s approach to its task and possible report structure.
3) Draft agenda for the weight-of-evidence workshop and possible speakers.
4) Schedule and agendas for future meetings.
The following materials (written documents) were made available to the committee in the closed sessions:
11. Letter and two articles—Linear low-dose extrapolation for noncancer health effects is the exception, not the rule and Practical risk assessment and management issues arising were we to adopt low-dose linearity for all endpoints—from Lorenz R. Rhomberg to Ellen Mantus. Received on November 5, 2012.
12. Letter and two workshop discussion drafts from the American Chemistry Council to Ellen Mantus dated November 6, 2012.
13. Revised workshop discussion draft from the American Chemistry Council sent to Ellen Mantus on November 15, 2012.
14. Letter submitted by Kimberly Wise on behalf of the American Chemistry Council’s Chlorine Chemistry Division to Ellen Mantus dated November 26, 2012.
15. Letter submitted by Michael Dourson on behalf of the Alliance for Risk Assessment Dose Response Advisory Committee to Ellen Mantus dated November 30, 2012.
16. Preamble to IRIS Toxicological Reviews. Received from Norman Birchfield, EPA, on December 7, 2012.
17. Research Integrity Roundtable. Press Release and Report – Improving the Use of Science in Regulatory Decision-Making: Dealing with Conflict of Interest and Bias in Scientific Advisory Panels, and Improving Systematic Scientific Reviews. Received from Colleen Briley Daywalt, The Keystone Center, on October 1, 2012.
18. Overview of the Current Process for Development of IRIS Assessments. A PowerPoint presentation to the Committee to Review the IRIS Process by Vincent Cogliano, EPA, on December 13, 2012, in Irvine, CA.
19. Improvements to the Developments of the IRIS Health Assessments – Step 1. Literature Search Strategy and Identification of Evidence. A PowerPoint presentation to the Committee to Review the IRIS Process by Vincent Cogliano (for Glinda Copper), EPA, on December 13, 2012, in Irvine, CA.
20. Improvements to the Developments of the IRIS Health Assessments – Step 2. Evaluation of Evidence. A PowerPoint presentation to the Committee to Review the IRIS Process by Samantha Jones, EPA, on December 13, 2012, in Irvine, CA.
21. Improvements to the Developments of the IRIS Health Assessments – Step 3. Synthesis and Integration of Evidence. A PowerPoint presentation to the Committee to Review the IRIS Process by Lynn Flowers, EPA, on December 13, 2012, in Irvine, CA.
22. Improvements to the Developments of the IRIS Health Assessments – Steps 4 and 5. Selection of Studies and Derivation of Toxicity Values. A PowerPoint presentation to the Committee to Review the IRIS Process by Weihsueh A. Chiu, EPA, on December 13, 2012, in Irvine, CA.
23. Systematic Review and Evidence Integration for Literature-Based Assessments. A PowerPoint presentation to the Committee to Review the IRIS Process by Kristina Thayer, NTP, on December 13, 2012, in Irvine, CA.
24. Retooling of IRIS: What Progress Has Actually Been Made Over the Last 20 Months? Unfinished Business: Recommendations for the Path Forward to Success. A PowerPoint presentation at the Society for Risk Analysis Annual Meeting by Rick Becker, ACC, on December 12, 2012. Received on December 13, 2012.
Date of posting of Closed Session Summary:
December 27, 2012
